Recent

% | $
Quotes you view appear here for quick access.

Lpath Inc. Message Board

  • sailorhughes sailorhughes Mar 26, 2013 12:08 PM Flag

    Milestones and targets as presented by LPath from 2010 presentation

    First item of significance is that they are almost all mentioned in the 2013 Roth Presentation and second not one was accomplished on time and most are still pending.

    1Q 2011 – Dose the first patient in the iSONEP Phase Ib clinical trial (PEDigree) in wet age-related
    macular degeneration (AMD) patients with Retinal Pigment Epithelial detachment.

    2Q 2011 – Dose the first patient in the iSONEP Phase IIa clinical trial (Nexus) in wet age-related
    macular degeneration (AMD) patients, possibly with occult disease.

     3Q 2011 – Final patient enrolled in the iSONEP Phase Ib clinical trial in wet age-related macular
    degeneration (AMD) patients with Retinal Pigment Epithelial detachment.

     3Q 2011 – Partner Lpathomab.

     4Q 2011 – Preliminary results from the iSONEP Phase Ib clinical trial in wet age-related macular
    degeneration (AMD) patients with Retinal Pigment Epithelial detachment.

     4Q 2011 – Form a collaboration for the ImmuneY2™ platform technology.

     1Q 2012 – Initiate clinical trial of ASONEP in renal cell carcinoma (RCC).

     1Q 2012 – Initiate clinical trial of ASONEP in neuroblastoma.

     1Q 2012 – Announce a preclinical candidate for Lpathomab.

     2Q 2012 – Final patient enrolled in the iSONEP Phase IIa clinical trial in wet age-related macular
    degeneration (AMD) patients.

     4Q 2012 – Preliminary results from the ASONEP renal cell carcinoma (RCC) clinical trial.

     1Q 2013 – Pfizer decision to opt in to the iSONEP program.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
LPTN
2.26+0.0300(+1.35%)Apr 17 4:00 PMEDT